A U.S. appeals court ruled invalid patents owned by Jazz Pharmaceuticals covering the company’ narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals to launch a generic version of the medicine.
Startup Harmony Biosciences spun out of France-based Paragon Biosciences with $270 million in financing and the exclusive U.S. rights to narcolepsy drug pitolisant.
206 million American adults struggling to get a good night’s rest seek out sleep management solutions to deal with conditions such as insomnia, sleep apnea, narcolepsy, and more.
The U.S. Food and Drug Administration approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc’s drug to treat patients with narcolepsy, a kind of sleeping disorder.
Scientists investigating why a GlaxoSmithKline flu vaccine triggered narcolepsy in some people say they have the first solid evidence the rare sleep disorder may be a so-called “hit-and-run” autoimmune disease. The researchers were trying to find out why, of two different flu vaccines widely deployed during the 2009/2010 swine flu pandemic, only one — GSK’s […]